Chapter 3: Pharmacodynamics — Module 2: Dose-Response Relationships, Therapeutic Index and Concentration-Effect Analysis
1. A 67-year-old man with atrial fibrillation and a history of digitalis sensitivity is admitted with palpitations, nausea, and visual disturbances. His serum digoxin level is 1.4 ng/mL -- within the conventional therapeutic range of 0.5-2.0 ng/mL. His serum potassium is 2.9 mEq/L. Which of the following best explains why this patient is experiencing digoxin toxicity at a seemingly therapeutic drug concentration?
A) Hypokalemia causes membrane hyperpolarization in myocardial cells, which increases the voltage threshold for Na/K-ATPase activation, allowing digoxin to inhibit a greater proportion of pumps at any given plasma concentration
B) Hypokalemia is relevant only because it reflects underlying diuretic use, which has independently altered digoxin's volume of distribution through renal tubular competition, raising the effective intracardiac digoxin concentration above what the serum level reflects
C) Hypokalemia and digoxin toxicity share the clinical syndrome of AV block, but they operate through completely independent mechanisms with no pharmacodynamic interaction -- the patient's toxicity reflects measurement error in his digoxin assay rather than true drug excess
D) Hypokalemia has no direct pharmacodynamic interaction with digoxin -- it is pharmacokinetically relevant because low potassium reduces digoxin's renal clearance, raising serum digoxin concentrations above the measured level through redistribution from tissue stores
E) Hypokalemia reduces the competing potassium concentration at the extracellular K+-binding site of the Na/K-ATPase pump -- since potassium and digoxin compete for binding at this site, low extracellular K+ allows digoxin to bind more avidly to Na/K-ATPase, shifting the digoxin concentration-effect curve leftward and producing toxicity at serum concentrations that would be safe in a normokalemic patient
ANSWER: E
Rationale:
This case illustrates pharmacodynamic sensitization -- a shift in the concentration-effect relationship such that the same drug concentration produces greater effect than it would under baseline conditions. Digoxin inhibits Na/K-ATPase by binding to the extracellular K+-binding site of the enzyme's alpha subunit. Potassium and digoxin compete for this binding site -- elevated extracellular potassium reduces digoxin binding (which is why hyperkalemia is used to treat digoxin toxicity in some settings), while reduced extracellular potassium (hypokalemia) reduces competition and allows digoxin to bind more avidly. The pharmacodynamic consequence is a leftward shift in the digoxin concentration-effect curve: the EC50 (the concentration producing 50% inhibition of Na/K-ATPase) falls, meaning that lower digoxin concentrations produce the same degree of pump inhibition and the same arrhythmogenic effect. A digoxin level of 1.4 ng/mL that would be safe in a normokalemic patient produces toxicity when potassium is 2.9 mEq/L because the effective pharmacodynamic exposure -- the degree of Na/K-ATPase inhibition -- is substantially greater. This explains why the conventional therapeutic range for digoxin is defined assuming normal electrolytes, and why maintaining normokalemia is a cornerstone of safe digoxin use. Loop diuretics and thiazides -- frequently co-prescribed with digoxin in heart failure -- are a common cause of this interaction.
Option A: Option A is incorrect -- hypokalemia produces membrane depolarization (more positive resting potential), not hyperpolarization; and the mechanism of increased digoxin sensitivity is competitive binding at the K+ site, not voltage-threshold changes.
Option B: Option B is incorrect -- diuretics do not significantly alter digoxin's volume of distribution through renal tubular competition in a way that raises intracardiac concentrations above serum levels; the pharmacodynamic mechanism is the correct explanation.
Option C: Option C is incorrect -- hypokalemia and digoxin have a well-characterized pharmacodynamic interaction at Na/K-ATPase; this is not a measurement artifact.
Option D: Option D is incorrect -- while hypokalemia does reduce renal digoxin clearance to some extent, the primary mechanism of increased toxicity at normal digoxin levels is pharmacodynamic sensitization through reduced K+ competition at the binding site, not pharmacokinetic redistribution.
2. A 28-year-old woman with newly diagnosed generalized epilepsy is started on valproic acid 500 mg twice daily. Two months later lamotrigine is added for better seizure control. Within three weeks she develops ataxia, diplopia, and nausea. Her lamotrigine level is found to be nearly double the expected value for her dose. Which of the following best explains this drug interaction?
A) Lamotrigine displaces valproic acid from plasma protein binding (albumin), transiently increasing free valproic acid concentrations, which then competitively inhibits lamotrigine's renal tubular secretion, producing net lamotrigine accumulation
B) Valproic acid and lamotrigine are pharmacodynamically synergistic at voltage-gated sodium channels, producing additive CNS toxicity at combined concentrations that would individually be tolerated; the elevated lamotrigine level is an assay artifact from cross-reactivity with valproic acid metabolites
C) Valproic acid inhibits the UGT (uridine diphosphate glucuronosyltransferase) enzymes -- primarily UGT1A4 and UGT2B7 -- responsible for lamotrigine's primary elimination pathway (glucuronidation); reduced lamotrigine clearance causes drug accumulation to nearly double the expected concentration, producing dose-dependent CNS toxicity
D) Lamotrigine induces CYP2C9 in the hepatic microsomal system, paradoxically increasing the rate of valproic acid metabolism to its toxic 4-en-valproic acid metabolite, producing indirect lamotrigine toxicity through metabolite-mediated mitochondrial dysfunction
E) Lamotrigine inhibits the hepatic UGT enzymes responsible for valproic acid glucuronidation, raising valproic acid levels; the elevated valproic acid then pharmacodynamically potentiates lamotrigine's CNS effects through enhanced GABA-mediated inhibition without altering lamotrigine pharmacokinetics
ANSWER: C
Rationale:
This is one of the most clinically important pharmacokinetic drug interactions in epilepsy management. Lamotrigine's primary route of elimination is hepatic glucuronidation, catalyzed by UGT1A4 and UGT2B7 -- approximately 90% of lamotrigine is cleared by this pathway. Valproic acid is a potent inhibitor of UGT enzymes, particularly UGT1A4 and UGT2B7. When valproic acid is co-administered with lamotrigine, it inhibits lamotrigine's glucuronidation, reducing lamotrigine clearance by approximately 50%. The consequence is that lamotrigine plasma concentrations approximately double for any given dose -- precisely what is observed in this case. The clinical syndrome (ataxia, diplopia, nausea) represents classic lamotrigine dose-dependent toxicity. This interaction is so well-characterized that lamotrigine dosing guidelines specifically state that when added to valproic acid, the initial lamotrigine dose and titration rate must be halved compared to lamotrigine monotherapy. The interaction is pharmacokinetic -- valproic acid raises lamotrigine concentrations -- not pharmacodynamic synergism, though both mechanisms could in principle contribute.
Option A: Option A is incorrect -- the interaction is not through protein binding displacement and renal tubular competition; protein binding displacement alone rarely produces clinically meaningful interactions.
Option B: Option B is incorrect -- the elevated lamotrigine level is real, not an assay artifact; the pharmacodynamic synergism argument is a distractor.
Option D: Option D is incorrect -- lamotrigine does not induce CYP2C9 and does not produce indirect toxicity through valproic acid metabolite formation; the interaction runs in the opposite direction.
Option E: Option E is incorrect -- the direction of UGT inhibition is reversed; it is valproic acid inhibiting lamotrigine's UGT-mediated clearance, not lamotrigine inhibiting valproic acid glucuronidation.
3. A clinical pharmacologist compares two anxiolytics for a patient with severe generalized anxiety disorder. Drug X has an Emax of 80% anxiolysis and an EC50 of 5 ng/mL. Drug Y has an Emax of 40% anxiolysis and an EC50 of 0.5 ng/mL. A resident argues that Drug Y should be preferred because it is 10-fold more potent. The clinical pharmacologist disagrees. Which of the following best supports the clinical pharmacologist's position?
A) Drug Y's higher potency is pharmacodynamically irrelevant if the patient requires more than 40% anxiolysis for functional improvement -- Drug Y's Emax of 40% is an absolute ceiling that cannot be exceeded regardless of dose; a patient whose disease severity demands 60-80% symptom reduction can only achieve that with Drug X, making Drug X's higher efficacy the clinically decisive parameter despite its lower potency
B) Drug Y's higher potency means it will achieve full receptor occupancy at lower doses than Drug X -- once full occupancy is achieved, the Emax of both drugs becomes equal because all receptors are maximally activated regardless of intrinsic efficacy differences
C) Both potency and efficacy are irrelevant to anxiolytic drug selection -- clinical superiority is determined entirely by tolerability profile, onset of action, and patient preference rather than by pharmacodynamic parameters
D) The resident is correct -- potency is the primary determinant of clinical utility for anxiolytics because lower EC50 values mean the drug can be dosed less frequently, reducing the total daily pill burden and improving patient adherence
E) Drug X's lower potency means it requires higher plasma concentrations for effect, which inevitably produces more adverse effects through off-target receptor activation at the higher concentrations required, making Drug Y safer regardless of the Emax difference
ANSWER: A
Rationale:
The clinical pharmacologist's position rests on the pharmacodynamic principle that Emax is the ceiling of achievable effect and cannot be overcome by increasing dose. Drug Y, despite its superior potency (10-fold lower EC50), has an Emax of only 40% anxiolysis. For a patient with severe generalized anxiety disorder requiring substantial symptom reduction for functional improvement, Drug Y's ceiling is simply inadequate -- at any dose, it cannot produce more than 40% anxiolysis. Drug X, despite requiring 10-fold higher concentrations to achieve equivalent intermediate effects, can produce up to 80% anxiolysis at its Emax. If the patient needs 60-70% symptom reduction to function adequately, Drug Y is pharmacologically incapable of providing it regardless of how the dose is adjusted. Potency matters clinically when drugs are being compared for equivalent efficacy -- a more potent drug of the same class achieves the same effect at lower doses (fewer tablets, lower cost, sometimes better tolerability). But when Emax differs, efficacy becomes the decisive selection criterion. This principle applies broadly: in heart failure, partial agonists at beta-adrenergic receptors cannot provide the inotropic support of full agonists when maximum stimulation is required; in cancer pain, partial opioid agonists cannot substitute for full agonists when the pain severity demands maximum receptor activation.
Option B: Option B is incorrect -- full receptor occupancy by a partial agonist does not produce the same effect as full receptor occupancy by a full agonist; intrinsic efficacy determines the response per occupied receptor, and a partial agonist produces less effect per receptor regardless of occupancy level.
Option C: Option C is incorrect -- while tolerability and onset are clinically important, they do not supersede the fundamental pharmacodynamic constraint that Emax represents an absolute ceiling.
Option D: Option D is incorrect -- potency does not determine dosing frequency; dosing interval is governed by pharmacokinetic half-life, not by EC50.
Option E: Option E is incorrect -- lower potency does not inevitably produce more adverse effects; Drug X's higher concentration requirements might be achievable without off-target toxicity depending on its selectivity profile; this is an empirical question, not a pharmacodynamic certainty.
4. A 45-year-old man with refractory partial seizures is stable on phenytoin with a free phenytoin level of 1.8 mcg/mL (therapeutic range 1-2 mcg/mL for free phenytoin). His physician plans to add fluconazole for an oral candidiasis infection. What is the most appropriate management of his phenytoin therapy?
A) No dose adjustment is needed -- phenytoin has a wide therapeutic index with a large margin between therapeutic and toxic concentrations, and CYP2C9 inhibition by fluconazole will only modestly raise phenytoin levels within an acceptable range
B) Phenytoin levels should be checked once at 7 days after fluconazole initiation -- if the level remains within the therapeutic range at that point, no further monitoring is required for the duration of fluconazole therapy
C) Dose reduction is unnecessary but phenytoin should be switched to an alternative antiepileptic drug not metabolized by CYP2C9, such as levetiracetam, for the duration of fluconazole treatment, then switched back afterward
D) Close monitoring of free phenytoin levels is required within days of starting fluconazole, with a high index of suspicion for toxicity and probable dose reduction; because phenytoin's CYP2C9-mediated metabolism is already near saturation at therapeutic concentrations, even partial CYP2C9 inhibition by fluconazole can produce a disproportionately large rise in plasma phenytoin concentrations, pushing a previously therapeutic level into the toxic range
E) Fluconazole should be avoided entirely in any patient on phenytoin -- the interaction is absolutely contraindicated because the risk of phenytoin toxicity cannot be managed with dose adjustment or monitoring
ANSWER: D
Rationale:
This scenario requires integration of phenytoin's non-linear pharmacokinetics with the clinical implications of CYP2C9 inhibition. Phenytoin at therapeutic concentrations (free level 1.8 mcg/mL, near the upper end of the therapeutic range) is operating on the near-vertical portion of its Michaelis-Menten elimination curve -- CYP2C9-mediated hydroxylation is already approaching saturation. Fluconazole is a potent CYP2C9 inhibitor that acts by coordinating its triazole nitrogen with the heme iron of CYP2C9, reducing the enzyme's metabolic capacity. When the already-nearly-saturated CYP2C9 is further inhibited by fluconazole, phenytoin elimination is substantially reduced and plasma concentrations rise disproportionately -- a small inhibitory effect on Vmax produces a large increase in steady-state concentration because the system is on the steep part of the saturation curve. Free phenytoin levels should be checked within 3-5 days of fluconazole initiation, not at 7 days, because toxicity can develop rapidly. Clinical signs of phenytoin toxicity -- nystagmus (first sign), ataxia, diplopia, drowsiness, and at higher levels confusion and seizure exacerbation paradoxically -- should prompt immediate level checking. Dose reduction is frequently required. The interaction is important but manageable with vigilant monitoring, not an absolute contraindication.
Option A: Option A is incorrect -- phenytoin has a narrow therapeutic index, not a wide one; the combination with a CYP2C9 inhibitor at near-saturating phenytoin concentrations is high-risk and requires active management.
Option B: Option B is incorrect -- 7 days is too late for initial monitoring; toxicity can develop within 2-4 days of CYP2C9 inhibitor addition; a single check is also insufficient given the dynamic nature of the interaction.
Option C: Option C is incorrect -- switching antiepileptic drugs mid-therapy carries its own risks including breakthrough seizures during the transition; careful monitoring and dose adjustment is a more appropriate approach than drug substitution for a short course of fluconazole.
Option E: Option E is incorrect -- the interaction is clinically manageable with appropriate monitoring and dose adjustment; absolute contraindication is not warranted and would deny the patient effective antifungal therapy unnecessarily.
ANSWER KEY: Q1=E Q2=C Q3=A Q4=D
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.